Caliper Life Sciences, Inc. today reported financial results for the quarter ended March 31, 2006. Total revenues for the first quarter were $22.3 million, an increase of 21% from $18.4 million in the first quarter of 2005. Excluding unfavorable effects of foreign
exchange rate movements, revenues increased from the prior year quarter by 24%, which includes 11% organic growth.
Yahoo
News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Health Canada Opens Consultation on ‘Pause the Clock’ Proposal
The agency would be able to pause the clock for medical device applications linked together that have different review times.
FDA Approves First Immuno-Oncology Drug for Certain Patients Previously Treated for Lung Cancer
The agency said continuing approval for Opdivo may depend on the drug showing clinical benefit in future clinical trials.
FDAnews Drug Daily Bulletin
CALIPER LIFE SCIENCES REPORTS Q1 2006 FINANCIAL RESULTS
May 11, 2006